行情

ACER

ACER

Acer Therapeutic
NASDAQ

实时行情|Nasdaq Last Sale

3.330
+0.200
+6.39%
盘后: 3.200 -0.13 -3.90% 17:58 11/15 EST
开盘
3.170
昨收
3.130
最高
3.340
最低
3.160
成交量
4.07万
成交额
--
52周最高
28.25
52周最低
1.871
市值
3,361.69万
市盈率(TTM)
-1.0532
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ACER 新闻

  • Acer Therapeutics EPS beats by $0.05
  • seekingalpha.4天前
  • Acer Therapeutics Q3 EPS $(0.52) Down From $(0.43) YoY
  • Benzinga.4天前
  • Acer Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
  • GlobeNewswire.4天前
  • 沪指震荡收低、制造业PMI回落 标普500指数创新高
  • 新浪财经.10/31 09:20

更多

所属板块

生物技术和医学研究
+1.25%
制药与医学研究
+1.34%

热门股票

名称
价格
涨跌幅

ACER 简况

Acer Therapeutics Inc., formerly Opexa Therapeutics, Inc., is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The Company is developing Edsivo for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the United States. The Company is developing ACER-001, a pharmacologic treatment option for the treatment of Maple Syrup Urine Disease (MSUD). ACER-001 is an immediate-release formulation of sodium phenylbutyrate (NaPB) developed using a microencapsulation process. The Company is also developing ACER-001 for the treatment of Urea Cycle Disorders (UCD).
展开

Webull提供Acer Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。